Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review

M Ishida, Y Kuroiwa, E Yoshida, M Sato… - Modern …, 2018 - academic.oup.com
Objectives: To identify, describe and summarize evidence on residual symptoms and
disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low …

[PDF][PDF] Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis

G Furneri, LG Mantovani, A Belisari, M Mosca… - Clinical and …, 2012 - iris.sssup.it
Objective. To provide a state of the art of economic analyses applied to rheumatoid arthritis
(RA). Methods. A systematic literature review on economic consequences and …

Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement

NA Goyal, TM Cash, U Alam, S Enam… - Journal of Neurology …, 2016 - jnnp.bmj.com
Objectives To explore phenotypic differences between individuals with sporadic inclusion
body myositis (sIBM) who are seropositive for the NT5c1A antibody compared with those …

A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study

S Hirata, L Dirven, Y Shen, M Centola, G Cavet… - …, 2013 - academic.oup.com
Objective. To evaluate a multi-biomarker disease activity (MBDA) score, a novel index based
on 12 serum proteins, as a tool to guide management of RA patients. Methods. A total of 125 …

Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients

A Dalbeni, A Giollo, M Bevilacqua, G Cioffi… - Hypertension …, 2020 - nature.com
Patients with rheumatoid arthritis (RA) have an increased incidence of cardiovascular
events. Ultrasound examination of the carotid arteries can show the presence of plaques …

Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission

C Barnabe, NX Thanh, A Ohinmaa, J Homik… - Annals of the …, 2013 - ard.bmj.com
Objective Determine healthcare service utilisation costs among patients using biological
therapies for rheumatoid arthritis (RA), considering the magnitude and duration of patient …

Traditional cardiovascular risk factors or inflammation: Which factors accelerate atherosclerosis in arthritis patients?

A Dalbeni, A Giollo, A Tagetti, S Atanasio… - International Journal of …, 2017 - Elsevier
Patients with chronic inflammatory arthritis experience an increased incidence of
cardiovascular (CV) events. In addition to visualizing atherosclerotic plaques, ultrasound …

[HTML][HTML] Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical …

M Backhaus, J Kaufmann, C Richter… - Clinical …, 2015 - Springer
Tocilizumab (TCZ) and tumour necrosis factor inhibitors (TNFi) are recommended for the
treatment of rheumatoid arthritis (RA) in patients with inadequate response (IR) to prior …

[HTML][HTML] Value of remission in patients with rheumatoid arthritis: a targeted review

AJ Ostor, R Sawant, CZ Qi, A Wu, O Nagy, KA Betts - Advances in Therapy, 2022 - Springer
The treat-to-target strategy, which defines clinical remission as the primary therapeutic goal
for rheumatoid arthritis (RA), is a widely recommended treatment approach in clinical …

The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990–2010: before and after introduction of biologic agents

E Hallert, M Husberg, L Bernfort - Rheumatology, 2012 - academic.oup.com
Objective. To explore the incidence of disability pension (DP) due to RA as an estimation of
permanent work disability before and after introduction of biologic drugs. Methods. The …